Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways

Hypertension Research

Volumn 34, Issue 3, 2011, Pages 341-347

  Takayama, Narimasa ^a   Kai, Hisashi ^a   Kudo, Hiroshi ^a   Yasuoka, Suguru ^a   Mori, Takahiro ^a   Anegawa, Takahiro ^a   Koga, Mitsuhisa ^a   Kajimoto, Hidemi ^a   Hirooka, Yoshitaka ^b   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

blood pressure variability; cardiac hypertrophy; signaling; statin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; LIPID; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOLLAGEN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE VARIABILITY; CONTROLLED STUDY; DENERVATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HYPERTENSION; LIPID BLOOD LEVEL; MACROPHAGE MIGRATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CAROTID SINUS; CELL ENLARGEMENT; CHOLESTEROL; DENERVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIPOPROTEINS, HDL; MALE; MONOMERIC GTP-BINDING PROTEINS; MYOCYTES, CARDIAC; RATS; RATS, INBRED SHR; RHOA GTP-BINDING PROTEIN; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES; VENTRICULAR REMODELING;

EID: 79952416283     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.229     Document Type: Article

References (48)

1. Yano Y, Kario K. Unresolved issues of the morning blood pressure surge: the next stage of clinical applicability for the morning surge. Hypertens Res 2008;31: 1491-1494.
2. Metoki H, Ohkubo T, Imai Y. Diurnal blood pressure variation and cardiovascular prognosis in a community-based study of Ohasama, Japan. Hypertens Res 2010;33: 652-656.
3. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, Grassi G, di Rienzo M, Pedotti A, Zanchetti A. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983;53: 96-104. (Pubitemid 13031772)
4. Floras JS, Hassan MO, Jones JV, Osikowska BA, Sever PS, Sleight P. Factors influencing blood pressure and heart rate variability in hypertensive humans. Hypertension 1988;11: 273-281.
5. Canonico V, De Caprio L, Vigorito C, Forgione L, Tedeschi C, Guarini P, Rengo F. Differences in blood pressure profile between young and elderly hypertensive patients. J Hum Hypertens 1990;4: 405-409. (Pubitemid 20260459)
6. Zakopoulos NA, Tsivgoulis G, Barlas G, Papamichael C, Spengos K, Manios E, Ikonomidis I, Kotsis V, Spiliopoulou I, Vemmos K, Mavrikakis M, Moulopoulos SD. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 2005;45: 505-512. (Pubitemid 40411251)
7. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-h blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987;5: 93-98. (Pubitemid 17058039)
8. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, Ferrario M, Mancia G. Blood pressure variability and organ damage in a general population: Results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002;39: 710-714. (Pubitemid 34165211)
9. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, Prontera C, Emdin M, Flacco M, Schillaci G, De Caterina R. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res 2009;31: 2137-2146.
10. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study. Hypertension 2000;36: 901-906.
11. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, Jaaskivi M, Nachev C, Parati G, O'Brien ET, Tuomilehto J, Webster J, Bulpitt CJ, Fagard RH. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertension 2003;21: 2251-2257. (Pubitemid 38293563)
12. Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S, Hashimoto M, Ako J, Iijima K, Sudoh N, Yoshizumi M, Ouchi Y. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005;28: 1-7. (Pubitemid 40584956)
13. Kudo H, Kai H, Kajimoto H, Koga M, Takayama N, Mori T, Ikeda A, Yasuoka S, Angawa T, Mifune H, Kato S, Hirooka H, Imaizumi T. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009;54: 832-838.
14. Kai H, Kudo H, Takayama N, Yasuoka S, Kajimoto H, imaizumi T. Large blood pressure variability and hypertensive cardiac remodeling -Role of cardiac inflammation. Circ J 2009;73: 2198-2203.
15. Liao JK. Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 2004;52: 248-253. (Pubitemid 39360341)
16. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51: 415-426.
17. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alpha1- adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 1996;271: 31185-31190. (Pubitemid 26408561)
18. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108: 1429-1437. (Pubitemid 33091980)
19. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93: 767-775. (Pubitemid 37288672)
20. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19: 26-37. (Pubitemid 28094090)
21. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003;285: H938-H945. (Pubitemid 37048146)
22. Krieger EM. Neurogenic hypertension in rat. Circ Res 1964;15: 511-521.
23. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-b function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106: 130-135. (Pubitemid 34747453)
24. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, Imaizumi T. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 1998;83: 594-601. (Pubitemid 28427742)
25. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, Takemiya K, Koga M, Yamamoto T, Imaizumi T. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004;43: 499-503. (Pubitemid 38174161)
26. Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, Seki Y, Egashira K, Imaizumi T. Inhibition of intrinsic interferon-g function prevents neointima formation after balloon injury. Hypertension 2007;49: 909-915. (Pubitemid 351664225)
27. Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, Kusaba K, Kai M, Egashira K, Kataoka Y, Imaizumi T. Inhibition of progression and stabilization of plaques by therapeutic interferon-g function blocking in ApoE-KO mice. Circ Res 2007;101: 348-356. (Pubitemid 47267703)
28. Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW. Agonistinduced phosphorylation of the vascular type 1 angiotensin II receptors. Hypertension 1994;24: 523-527. (Pubitemid 24296478)
29. Tahara N, Kai H, Niiyama H, Mori T, Sugi Y, Takayama N, Yasukawa H, Numaguchi Y, Matsui H, Okamura K, Imaizumi T. Repeated gene transfers of naked prostacyclin synthase plasmid into skeletal muscles attenuate monocrotaline-induced pulmonary hypertension and prolong survival in rats. Human Gene Ther 2004;15: 1270-1278. (Pubitemid 40052438)
30. Kai H, Griendling KK, Lassègue B, Fukui T, Minieri CA, Alexander RW. Prolonged exposure to agonist results in a reduction in the levels of the Gq/G11 a-subunit in cultured vascular smooth muscle cells. Mol Pharmacol 1996;49: 96-104.
31. Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Cittadini A, Cardone L, Coppola C, Cavuto L, Arcucci O, Sacca L, Avvedimento EV, Chiariello M. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002;106: 2118-2124. (Pubitemid 35192819)
32. Sugden PH. Signaling in myocardial hypertrophy: Life after calcineurin? Circ Res 1999;84: 633-646. (Pubitemid 29157331)
33. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of frame: A decade of hypertrophic signaling hits. Circ Res 2006;98: 730-742.
34. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W, Kadowaki T, Yazaki Y. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res 1999;84: 458-466. (Pubitemid 29120012)
35. Thorburn J, Xu S, Thorburn A. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J 1997;16: 1888-1900. (Pubitemid 27170950)
36. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993;27: 341-348. (Pubitemid 23116130)
37. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: Interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999;41: 532-543. (Pubitemid 29130617)
38. Sadoshima J, Izumi S. The cellular and molecular response of cardiac mypcytes to mechanical stress. Annu Rev Physiol 1997;59: 551-571. (Pubitemid 27142455)
39. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya T, Murakami K, Yazaki Y. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1999;97: 1952-1959.
40. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rats. Cardiovasc Res 1992;26: 671-677.
41. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB. Inflammatory cells and myocardial fibrosis: Spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996;32: 1096-1107. (Pubitemid 26423399)
42. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction -Another model of inflammation-. Hypertension 2004;43: 739-745. (Pubitemid 38405580)
43. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: A critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res 1998;82: 666-676. (Pubitemid 28160707)
44. Delbosc S, Cristol JP, Descomps B,Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002;40: 142-147. (Pubitemid 34840089)
45. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100: 2131-2141.
46. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59: 646-654. (Pubitemid 32179945)
47. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 2006;33: 1164-1171. (Pubitemid 44923903)
48. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997;47: 904-909. (Pubitemid 27357013)